[1] Spearman CW, Dusheiko GM, Hellard M, et al. Hepatitis C. Lancet,2019,394:1451-1466.
[2] Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med,2001,194:1395-1406.
[3] Chen DY, Wolski D, Aneja J, et al. Hepatitis C virusspecific CD4+ T cell phenotype and function in different infection outcomes. J Clin Invest,2020, 130:768-773.
[4] Shin EC, Park SH, Nascimbeni M, et al. The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol,2013,87:4772-4777.
[5] Kurktschiev PD, Raziorrouh B, Schraut W, et al. Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigenspecific T-bet induction. J Exp Med,2014,211:2047-2059.
[6] Wolski D, Foote PK, Chen DY, et al. Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8(+) T Cells in Chronic versus Acute Infection. Immunity,2017,47:648-663,e8.
[7] Barili V, Fisicaro P, Montanini B, et al. Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. Nat Commun, 2020,11:604.
[8] Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med,2003, 197:1645-1655.
[9] Bengsch B, Seigel B, Ruhl M, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog,2010,6:e1000947.
[10] Utzschneider DT, Charmoy M, Chennupati V, et al. T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity,2016,45:415-427.
[11] Alfei F, Kanev K, Hofmann M, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature,2019,571:265-269.
[12] Cox AL, Mosbruger T, Lauer GM, et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology, 2005,42:104-112.
[13] Fitzmaurice K, Petrovic D, Ramamurthy N, et al. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut,2011,60:1563-1571.
[14] von Delft A, Donnison TA, Lourenco J, et al. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine,2018,36:313-321.
[15] Wieland D, Kemming J, Schuch A, et al. TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. Nat Commun,2017,8:15050.
[16] Hartnell F, Esposito I, Swadling L, et al. Characterising HCV specific CD4+ T-cells following viral-vectored vaccination, directly acting anti-virals and spontaneous viral cure. Hepatology,2020,72:1541-1555.
[17] Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med,2006,12:190-197.
[18] Drane D, Maraskovsky E, Gibson R, et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin,2009,5:151-157.
[19] Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med,2014,6:261ra153.
[20] Cox AL, Page K, Melia M, et al. LB10. A Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Vaccine to Prevent Chronic Hepatitis C Virus Infection in an at-Risk Population. Open Forum Infect Dis, 2019,6:S997-S997. |
